Managing early-onset type 2 diabetes in the individual and at the population level
Open accessThe DOI matches its Crossref record; 164 of the 169 references it cites were found in a registry or an index; none of the 151 sources its claims cite is checked for support yet.
Abstract
Early-onset type 2 diabetes (defined as type 2 diabetes diagnosed in people aged <40 years) is an increasingly prevalent condition with a more aggressive disease trajectory than late-onset type 2 diabetes. It is associated with accelerated microvascular and macrovascular complications, reduced life expectancy, and adverse pregnancy outcomes. Despite its rising incidence, global management strategies have mostly been extrapolated from studies in older adults with limited evidence specific to younger populations. In this Series paper, we aim to highlight the unique challenges in the management of early-onset type 2 diabetes and why current models of care are inadequate. We emphasise that early-onset type 2 diabetes necessitates proactive and combination treatment strategies to address weight, faster β-cell decline, worse insulin resistance, and rapidly progressing hyperglycaemia compared with late-onset type 2 diabetes. However, there is minimal evidence on how best to address these factors and clinical inertia risks contributing to glycaemic burden. Cardiovascular risk assessment tools underestimate long-term risk, contributing to low use of statin and antihypertensive therapy. Reproductive health remains a key concern, yet preconception and pregnancy care are inadequate, with low adherence to recommended interventions. Health-care systems are not optimised to address the distinct needs of young adults, and gaps in transitional care (from paediatric to adult services) contribute to disengagement and adverse outcomes. Addressing these challenges requires tailored management strategies that consider the unique metabolic and psychosocial factors in this population. In this Series paper, we summarise the evidence base for the management of early-onset type 2 diabetes, key evidence gaps, and discuss the multisectoral and transdisciplinary elements needed to achieve population-level prevention to reverse these concerning trends.
Overview
CoChat Summary
TL;DR
Early-onset type 2 diabetes (diagnosed <40 years) is rising globally and has a more aggressive course than late-onset disease, yet management and prevention strategies are largely extrapolated from older adults. This Lancet Series paper reviews the evidence and argues for proactive weight-focused, cardiovascular, reproductive, psychosocial, and multisectoral population-level approaches while highlighting major evidence gaps.
Key findings
- Early-onset type 2 diabetes is associated with accelerated microvascular and macrovascular complications, reduced life expectancy (~15 years of life lost when diagnosed <30 years), and adverse pregnancy outcomes. Global prevalence in people aged 20–39 years rose from 2.9% (63 million) in 2013 to 3.8% (260 million) in 2021, and obesity is predicted to affect more than 206 million people aged 5–19 years by 2030.
- Management should be weight-focused and proactive: early combination therapy reduced time-to-treatment failure by 48% in the VERIFY trial; metformin monotherapy is unlikely to achieve durable glycaemic control. Meta-analyses in children/adolescents showed SGLT-2 inhibitors reduced HbA1c (mean difference −0.93%; 95% CI −1.36 to −0.49) and GLP-1 receptor agonists reduced HbA1c (−1.01%; −1.26 to −0.76) and bodyweight (−1.6 kg; −2.83 to −0.36).
- Bariatric surgery can induce remission in adolescents with severe obesity and type 2 diabetes: in TEEN-LABS (242 adolescents), remission was 95% at 3 years and 57% at 10 years; a systematic review of 29 studies (4970 adolescents) found 90% remission at 5 years and pooled BMI reduction of 13.1 kg/m² (95% CI 11.6–14.4).
- Cardiovascular risk is underestimated, with a 3% increase in cardiovascular disease risk for every year earlier that type 2 diabetes is diagnosed under age 40 years; reproductive care is inadequate, and women with prior gestational diabetes have a 10-fold higher risk of progression to early-onset type 2 diabetes (HR 9.51; 95% CI 7.14–12.67). In LMICs, fewer than one in ten individuals receive guideline-based diabetes treatment.
Methods
- This is a Lancet Series paper (narrative review/synthesis), not an original primary study. The authors conducted a literature search on PubMed from database inception to Jan 11, 2025, restricted to English-language articles.
- Search terms included “type 2 diabetes”, “early-onset”, “youth-onset”, “management”, “prevention”, and “treatment”; the authors prioritised randomised controlled trials testing interventions, observational studies with glycaemic outcomes, and studies on prevention of obesity and type 2 diabetes in young people.
- The paper summarises the evidence base, key evidence gaps, and multisectoral/transdisciplinary elements needed for population-level prevention and management.
Limitations
- Stated in the text: young adults are substantially under-represented in diabetes research and clinical trials; evidence specific to early-onset type 2 diabetes is minimal; many recommendations have low GRADE certainty; there are no RCTs of statins specifically in early-onset type 2 diabetes; and long-term outcomes of bariatric surgery, GLP-1 receptor agonists on growth, and early cardiovascular/renal effects remain unclear.
- Evident from the text: the literature search was restricted to PubMed and English-language articles, and the paper is a narrative Series review rather than a systematic review with formal risk-of-bias assessment or meta-analytic methods.
- Evident from the text: the authors prioritised certain study designs and outcomes, which may introduce selection bias into the evidence summarised.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
0 Valid · 7 Not valid · 90 Not checked · 33 Own results and interpretations
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As outlined in this Series, most early-onset diabetes cases are accompanied by excess adiposity.”
§ Managing early-onset type 2 diabetes in the individual and at the population level > Pharmacotherapy
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A check of a cited source is scheduled, or we don’t hold its full text yet; the claim is checked once it runs.
In the paper
“The SEARCH study 46 found that young adults with type 2 diabetes were often lost to follow-up and effective approaches to tackle this attrition are required.”
§ Managing early-onset type 2 diabetes in the individual and at the population level > Why early-onset type 2 diabetes needs a different approach
What the sources say
- Not checked yetcites [46] Agarwal, 2018, Transfer from paediatric to adult care for young adults with type 2 diabetes: the SEARCH for Diabetes in Youth Study, Diabet Med source
A check is scheduled.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not checked yet
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the probability of alternative diabetes subtypes in those diagnosed before age 40 years is higher, including type 1 and monogenic diabetes.”
§ Managing early-onset type 2 diabetes in the individual and at the population level > Why early-onset type 2 diabetes needs a different approach
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, metformin monotherapy is unlikely to achieve durable glycaemic control.”
§ Managing early-onset type 2 diabetes in the individual and at the population level > Pharmacotherapy
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“One option highlighted by a study in Taiwan showed that the implementation of financial incentives for health-care providers to deliver integrated care to those younger than 40 years with type 2 diabetes resulted in improved cardiovascular outcomes and mortality over 15 years of follow-up.47”
§ Managing early-onset type 2 diabetes in the individual and at the population level > Why early-onset type 2 diabetes needs a different approach
What the sources say
- Not checked yetcites [47] Yen, 2022, Long-term outcomes of the pay-for-performance program for patients with young-onset (20–40 years of age) type 2 diabetes, Diabetes Res Clin Pract source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
54 more claims
Create a free account to see all 130 claims and to verify the 138 references still open.
- It may state two separate claims as one. 56
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to physical complications, existing evidence suggests that EOT2D is associated with unique psychosocial challenges and an increased risk of mental health comorbidities (the presence of two or more conditions), such as anxiety, depression and diabetes‐related distress.”
From Psychosocial care and experiences in young adults living with early‐onset type 2 diabetes: A narrative review (2026) · cites this paper as [7]
In the citing paper
“Recent recommendations for the management of EOT2D have highlighted the importance of mental well‐being, identifying it as an essential component of care and a key treatment target.”
From Psychosocial care and experiences in young adults living with early‐onset type 2 diabetes: A narrative review (2026) · cites this paper as [7]
In the citing paper
“Although unsurprising, these findings are of concern as rates of EOT2D are especially higher in these underserved groups, which are already typically more affected by social and health inequalities.”
From Psychosocial care and experiences in young adults living with early‐onset type 2 diabetes: A narrative review (2026) · cites this paper as [7]
In the citing paper
“The fundamental gap in the current management of EOT2D is the failure of traditional, episodic care models to mitigate the uniquely aggressive trajectory of EOT2D [28, 60].”
From Digital Management of Early-Onset Type 2 Diabetes: Empowerment, Challenges, and Future Outlook (2026) · cites this paper as [60]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Managing early-onset type 2 diabetes in the individual and at the population level > Pharmacotherapy
“metformin did not lead to significantly better outcomes than glimepiride, placebo, or rosiglitazone for glycaemic control”
§ Managing early-onset type 2 diabetes in the individual and at the population level > Pharmacotherapy
“(mean difference [MD] in glycated haemoglobin [HbA 1c ] -0•67%; 95% CI -1•65 to -0•31) or BMI (-0•64 kg/m²; -1•84 to -0•56)”
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Abarca-Gómez, L., Abdeen, Z. A., Hamid, Z. A., Abu-Rmeileh, N. M., Acosta-Cazares, B., Acuin, C., Adams, R. J., Aekplakorn, W., Afsana, K., Aguilar-Salinas, C. A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32129-3 · Cited by 7,482
Ong, K. L., Stafford, L. K., McLaughlin, S. A., Boyko, E. J., Vollset, S. E., Smith, A. E., Dalton, B. E., Duprey, J., Cruz, J. A., Hagins, H., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01301-6 · Cited by 6,146
Self-citationInterventions for preventing obesity in children
Brown, T., Moore, T. H., Hooper, L., Gao, Y., Zayegh, A., Ijaz, S., Elwenspoek, M., Foxen, S. C., Magee, L., O'Malley, C., et al. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001871.pub4 · Cited by 2,982
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095
Social determinants of health and diabetes: A scientific review
Hill-Briggs, F., Adler, N. E., Berkowitz, S. A., Chin, M. H., Gary-Webb, T. L., Navas-Acien, A., Thornton, P. L., & Haire-Joshu, D. (2021) · Diabetes Care · doi:10.2337/dci20-0053 · Cited by 1,732
Hampl, S. E., Hassink, S. G., Skinner, A. C., Armstrong, S. C., Barlow, S. E., Bolling, C. F., Avila Edwards, K. C., Eneli, I., Hamre, R., Joseph, M. M., et al. (2023) · Pediatrics · doi:10.1542/peds.2022-060640 · Cited by 1,389
Vounzoulaki, E., Khunti, K., Abner, S. C., Tan, B. K., Davies, M. J., & Gillies, C. L. (2020) · BMJ · doi:10.1136/bmj.m1361 · Cited by 1,150
Self-citationZhou, B., Rayner, A. W., Gregg, E. W., Sheffer, K. E., Carrillo-Larco, R. M., Bennett, J. E., Shaw, J. E., Paciorek, C. J., Singleton, R. K., Barradas Pires, A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)02317-1 · Cited by 1,013
Research works printed but not linked: 1
- 2021, Pregnancy outcomes in young women with youth-onset type 2 diabetes followed in the TODAY study, Diabetes Care, 45, 1038
Cited by
Early-onset type 2 diabetes: the next major diabetes transition
Luk, A., Wild, S. H., Jones, S., Anjana, R. M., Hivert, M.-F., McCaffrey, J., Gregg, E. W., & Misra, S. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00830-x · Cited by 81
Self-citationUnderstanding the drivers and consequences of early-onset type 2 diabetes
Lim, L.-L., Jones, S., Cikomola, J. C., Hivert, M.-F., & Misra, S. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01012-8 · Cited by 59
Self-citationDavies, M. J., Lim, S. K., Slater, T., Goldney, J., Philis‐Tsimikas, A., Franco, D. R., Lamptey, R., Yates, T. E., Tankova, T. I., & Lingvay, I. (2026) · Nature Reviews Disease Primers · doi:10.1038/s41572-026-00687-w · Cited by 61
Hay, S. I., Nam, P., Saqib, H., McLaughlin, S. A., Bisignano, C., Ostroff, S. M., Ng, M., Nomura, S., Schumacher, A. E., & Murray, C. J. L. (2026) · The Lancet Public Health · doi:10.1016/s2468-2667(26)00098-8 · Cited by 16
Santulli, G. (2025) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00239-3 · Cited by 10
Metadata
- Authors
- Misra, S., Khunti, K., Goyal, A., Gable, D., Armocida, B., Tandon, N., Sachdev, P., Wild, S. H., Hivert, M.-F., & Beran, D.
- Affiliations
- Imperial College Healthcare NHS Trust (GB)
- University of Leicester (GB)
- All India Institute of Medical Sciences Bhopal (IN)
- Istituto Superiore di Sanità (IT)
- All India Institute of Medical Sciences (IN)
- University of Nottingham (GB)
- University of Edinburgh (GB)
- Harvard University (US)
- University of Geneva (CH)
- Corresponding author
- Misra, Shivani
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2025-06
- Volume
- 405
- Issue
- 10497
- Pages
- 2341-2354
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4411538221
- Cited by
- 47
- References
- 169
- Citations by year
- 2026: 40 · 2025: 7
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet (publishedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Wellcome Trust
- National Institute for Health Research Imperial Biomedical Research Centre
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- early-onset type 2 diabetes, young adults, diabetes management, combination therapy, insulin resistance, hyperglycemia, cardiovascular risk assessment, statin therapy, antihypertensive therapy, preconception care, pregnancy outcomes, reproductive health, transition to adult care, care transitions, population-level prevention, models of care
- MeSH terms
- Adult, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Pregnancy, Age of Onset
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-20, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-20 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Managing early-onset type 2 diabetes in the individual and at the population level. https://app.cochat.ai/papers/10.1016/s0140-6736(25)01067-0
- The paper
- Misra, S., Khunti, K., Goyal, A., Gable, D., Armocida, B., Tandon, N., Sachdev, P., Wild, S. H., Hivert, M.-F., & Beran, D. (2025). Managing early-onset type 2 diabetes in the individual and at the population level. The Lancet. https://doi.org/10.1016/s0140-6736(25)01067-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.